Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous (under the skin or ...

Biliary Tract Cancer (BTC): KEYTRUDA may be combined with chemotherapy medicines to treat BTC, a cancer that affects the bile ducts or gallbladder. This treatment is for adults when the cancer has ...

When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo. The conversion to ...

Merck & Co’s checkpoint inhibitor Keytruda can be given half as often ... virtual congress. Giving a 400 mg dose of the PD-1 inhibitor every six weeks, rather than the approved dosing of 200 ...

KEYNOTE-811 study showed improved progression-free and overall survival with Keytruda combination. Keytruda's recommended dosing is 200 mg every three weeks or 400 mg every six weeks. The safety ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.

March 5 (Reuters) - Merck's (MRK.N), opens new tab injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics (HALO.O ...

Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that ...

Merck’s (NYSE:MRK) injectable based on an enzyme developed by South Korea-based Alteogen is the company’s answer to the upcoming patent cliff for intravenously delivered Keytruda, which ...

Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous (under the skin or SC) formulation of the blockbuster drug Keytruda (pembrolizumab).